Parexel to acquire functional service provider ExecuPharm

By Melissa Fassbender contact

- Last updated on GMT

Parexel has entered into a definitive agreement to acquire ExecuPharm. (Image: iStock/Ridofranz)
Parexel has entered into a definitive agreement to acquire ExecuPharm. (Image: iStock/Ridofranz)

Related tags: Pharmaceutical industry

Parexel has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP), in a deal that it said will add scale to meet growing demand.

King of Prussia, PA-based ExecuPharm​ provides clients with professionals in several areas, such as clinical monitoring or study management. The company also provides support with operational activities, including onboarding, training, line management, performance management, and policy administration.

"Functional services represent an established and growing model within the biopharmaceutical industry, and ExecuPharm has supported the growing demand for these services," ​Cristi L. Barnett, senior director, global public relations, Parexel, told Outsourcing-Pharma.com, adding that both companies see "continued FSP growth opportunities​."

According to the company, ExecuPharm has seen an 85% growth over the past three years, while working with many top 20 and mid-sized and small biopharma companies.

Josef von Rickenbach, Chairman and CEO, Parexel, explained that clients are increasingly using both programmatic and functional outsourcing models, in the company's press release issued this morning. 

With its acquisition of ExecuPharm, Rickenbach said its existing functional services offering and capabilities will be expanded in order to meet the growing market demand – allowing clients to “fulfill all of their clinical development outsourcing needs through a single company​.”

The acquisition, terms of which were not released, is expected to close in the next three weeks.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars